Physician profile
Heather Johnson
NPI 1366656449
$1,543.53
in general payments reported to CMS, 2019-2025
22 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $287 · 2023: $471 · 2024: $236 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $374.11 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $193.39 | 2021-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $178.91 | 2021-2025 | |
| Amgen INC. | $133.20 | 2021-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $128.63 | 2021-2024 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals Lp | $127.92 | 2021-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $63.39 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $52.61 | 2023-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $36.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.94 | 2021-2023 | Tradjenta, Jardiance |
| Abbvie INC. | $27.48 | 2021-2022 | |
| Biogen, INC. | $25.93 | 2025 | Skyclarys |
| Abbott Laboratories | $22.02 | 2021 | |
| Radius Health, INC. | $21.40 | 2024 | Tymlos |
| Esperion Therapeutics, INC. | $18.13 | 2025 | Nexletol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $18.08 | 2025 | Zubsolv |
| Axsome Therapeutics, INC. | $16.76 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.22 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $14.74 | 2021 | |
| Seqirus USA INC | $14.61 | 2022 | |
| Inspiremd Ltd | $14.23 | 2025 | Cguard Prime Carotid Stent System |
| Novartis Pharmaceuticals Corporation | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.